ReviewCurrent oncology reports2019
Systemic Therapy of Central Nervous System Metastases of Breast Cancer.
Review in Current oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- Real-world data on T-DM1 efficacy - results of a single-center retrospective study of HER2-positive breast cancer patients.Scientific reports · 2019Trial
- CAR-T Cell Therapy for Central Nervous System Tumors.Methods in molecular biology (Clifton, N.J.) · 2026Review
- Neutrophil membrane-coated circular RNA nanoparticles for targeted immunotherapy in HER2-positive breast cancer brain metastasis.Cell communication and signaling : CCS · 2025Article
- Real-world data on trastuzumab emtansine (TDM1) efficacy and safety: Results of a single-centre retrospective study of HER2-positive metastatic breast cancer patients.Scientific reports · 2025Article
- The Brain-Penetrant Pan-ErbB Inhibitor Poziotinib Effectively Targets HER2+ Breast Cancer Brain Metastases.Cancer research · 2025Article
- MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer.Future oncology (London, England) · 2025Article
- Male Occult Primary Breast Cancer Diagnosed with Small Bowel Metastases: A Case Report.Surgical case reports · 2025Article
- New Frontiers in the Treatment of Patients with HER2+ Cancer and Brain Metastases: Is Radiotherapy Always Useful?Cancers · 2024Review
- Overcoming brain-derived therapeutic resistance in HER2+ breast cancer brain metastasis.bioRxiv : the preprint server for biology · 2024Article
- Intracranial management of HER-2 overexpression breast cancer with extensive volume or symptomatic brain metastases.Frontiers in oncology · 2024Article
- Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype.Nature communications · 2023Article
- Neratinib for HER2-positive breast cancer with an overlooked option.Molecular medicine (Cambridge, Mass.) · 2023Review
- Refining Therapy in Patients with HER2-Positive Breast Cancer with Central Nervous System Metastasis.Breast care (Basel, Switzerland) · 2022Review
- Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis-The Adjuvant Role of Lifestyle Changes.Current oncology (Toronto, Ont.) · 2022Article
- Intracranial Response Rate in Patients with Breast Cancer Brain Metastases after Systemic Therapy.Cancers · 2022Review
- Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities.Nature communications · 2022Article
- Neurosurgical resection for locally recurrent brain metastasis.Neuro-oncology · 2021Article
- Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review.BMC cancer · 2021Review
- Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab.Therapeutic advances in medical oncology · 2021Article
- Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib.Breast cancer (Dove Medical Press) · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewHistorically, systemic treatment options for patients with breast cancer brain metastases have been very limited. This review focuses on important considerations for systemic therapy as well as ongoing clinical trials evaluating novel agents. RECENT
findingsFor patients with hormone receptor-positive brain metastases, endocrine therapy or chemotherapy options can be considered. The role of CDK4/6 inhibitors is being explored in ongoing trials. Patients with HER2-positive disease have a number of treatment options, including ado-trastuzumab emtansine (TDM1) or lapatinib-capecitabine, and there is emerging evidence of the efficacy of neratinib- and tucatinib-based chemotherapy combinations in the CNS. Triple-negative tumors may respond to chemotherapy. Although much progress remains to be made, a number of effective systemic treatment options are emerging, particularly for patients with HER2-positive disease. Ongoing clinical trials will help define the role of novel agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.